Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E288004-5mg | 5mg | In stock | $147.90 | |
E288004-10mg | 10mg | In stock | $246.90 | |
E288004-25mg | 25mg | In stock | $543.90 | |
E288004-50mg | 50mg | In stock | $939.90 | |
E288004-100mg | 100mg | In stock | $1,533.90 |
Highly potent and selective OX2antagonist; brain penetrant
Synonyms | N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonyl-amino]-N-(pyridin-3-ylmethyl)ethanamide | Q5323607 | SCHEMBL1040297 | UNII-VT87V86D7W | DTXSID101045254 | KJPHTXTWFHVJIG-UHFFFAOYSA-N | N-Ethyl-2-((6-methoxy-3-pyridinyl)((2-methylphenyl)sulfonyl |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | Highly potent, selective OX2receptor antagonist (IC50values are 2.3 nM and 1900 nM for OX2and OX1respectively). Displays negligible or no inhibition of a panel of 80 receptors. Blocks orexin-B- and orexin-A-invoked calcium mobilization in hOX2-expressing |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of OX 1 receptor;Antagonist of OX 2 receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonylamino]-N-(pyridin-3-ylmethyl)acetamide |
---|---|
INCHI | InChI=1S/C23H26N4O4S/c1-4-26(16-19-9-7-13-24-14-19)23(28)17-27(20-11-12-22(31-3)25-15-20)32(29,30)21-10-6-5-8-18(21)2/h5-15H,4,16-17H2,1-3H3 |
InChi Key | KJPHTXTWFHVJIG-UHFFFAOYSA-N |
Canonical SMILES | CCN(CC1=CN=CC=C1)C(=O)CN(C2=CN=C(C=C2)OC)S(=O)(=O)C3=CC=CC=C3C |
Isomeric SMILES | CCN(CC1=CN=CC=C1)C(=O)CN(C2=CN=C(C=C2)OC)S(=O)(=O)C3=CC=CC=C3C |
WGK Germany | 3 |
PubChem CID | 9981404 |
Molecular Weight | 454.54 |
Wikipedia | EMPA_(drug) |
---|---|
PubChem CID | 9981404 |
CAS Registry No. | 680590-49-2 |
ChEMBL Ligand | CHEMBL2385132 |
RCSB PDB Ligand | 7MA |
GPCRdb Ligand | EMPA |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2313142 | Certificate of Analysis | Oct 24, 2022 | E288004 |
B2313143 | Certificate of Analysis | Oct 24, 2022 | E288004 |
B2313144 | Certificate of Analysis | Oct 24, 2022 | E288004 |
B2313147 | Certificate of Analysis | Oct 24, 2022 | E288004 |
B2313148 | Certificate of Analysis | Oct 24, 2022 | E288004 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 45.45, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 22.73, Max Conc. mM: 50 |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H302:Harmful if swallowed |
Precautionary Statements | P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P317:IF SWALLOWED: Get medical help. |
WGK Germany | 3 |
RIDADR | NONHforallmodesoftransport |
1. Rappas M, Ali AAE, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Doré AS et al.. (2020) Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.. J Med Chem, 63 (4): (1528-1543). [PMID:31860301] |